Efficacy and Safety of Losartan in Children With Ig A Nephropathy

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that using Losartan would help decrease proteinuria in controlling proteinuria in children with immunoglobulin A nephropathy.

Detailed Description
-----------------
Twenty nine patient with IgA nephropathy with proteinuria (urine protein to creatinine ratio > 0.3 mg/mg) were included in the study. All patients had received losartan treatment for 24 weeks. Changes in blood pressure, proteinuria, renal function, and biochemical parameters were prospectively evaluated before and at 4 weeks and 24 weeks.

Official Title
-----------------
A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy

Conditions
-----------------
Glomerulonephritis, IGA

Intervention / Treatment
-----------------
* Drug: Losartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: 2years or older and younger than 18 years Biopsy-proven Ig A Nephropathy Estimated GFR ≥ 90mL/min/m^2 Mean urinary protein-creatinine ratio > 0.3 g/g from three first-morning spot urine collections Exclusion Criteria: hypertension under dialysis or organ transplanted bilateral renal artery stenosis primary hyperaldosteronism pregnant

Ages Eligible for Study
-----------------
Minimum Age: 24 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Losartan treatement<br>All patients had received losartan treatment for 24 weeks. | Drug: Losartan<br>* Dose of Losartan : 0.7mg/kg once daily.<br>* Other names: Cozaar;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the change in urinary protein-creatinine ratio from baseline to the end of study | Change in urinary protein excretion, determined as urinary protein-creatinine ratio compared to baseline, after 24 weeks of treatment. | 24weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the change in urinary albumin-creatinine ratio from baseline to the end of study | Change in urinary albumin-creatinine ratio compared to baseline, after 24 weeks of treatment. | 24 weeks | 
| the proportion of patients wifh more than 50% decrease of urinary protein-creatinine ratio | Number of patients with wifh more than 50% decrease of urinary protein-creatinine ratio compared to baseline, after 24 weeks of treatment. | 24 weeks | 
| the proportion of patients wifh urinary protein-creatinine ratio < 0.2 at the end of study | Number of patients wifh urinary protein-creatinine ratio < 0.2 after 24 weeks of treatment. | 24 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Losartan, Ig A nephropathy, children, proteinuria